United Therapeutics Corporation / Fundamentals
Income statement
- Net revenue
€2.63B - Cost of goods sold
€289.24M - Gross profit
€2.34B - SG&A expenses
€651.91M - R&D expenses
€443.79M - EBITDA
€1.36B - D&A
€3.58M - EBIT
€1.24B - Interest expenses
€14.33M - EBT
€1.38B - Tax expenses
€151.06M - Net income
€1.06B
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
-€83.25M - Changes in working capital
€7.51M - Operating cash flow
€1.17B - Capex
€256.14M - Other investing cash flow
€1.03B - Net investing cash flow
-€599.37M - Total cash dividends paid
€0.00 - Issuance of common stock
€4.18M - Debt repayment
-€170.59M - Other financing cash flow
-€196.61M - Net financing cash flow
-€367.79M - Foreign exchange effects
€0.00 - Net change in cash
€202.49M - Cash at end of period
€1.36B - Free cash flow
€1.43B
Balance sheet
- Cash and cash equivalents
€1.36B - Cash and short-term investments
€1.36B - Total receivables
€323.52M - Inventory
€144.32M - Other current assets
€1.44B - Total current assets
€3.26B - Property, plant & equipment
€1.16B - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€1.64B - Other non-current assets
€198.99M - Total non-current assets
€3.48B - Total assets
€6.75B - Accounts payable
€0.00 - Short-term debt
€0.00 - Other current liabilities
€449.59M - Total current liabilities
€449.59M - Long-term debt
€0.00 - Deferred tax liabilities
€0.00 - Other non-current liabilities
€176.82M - Total non-current liabilities
€176.82M - Total liabilities
€626.41M - Common stock
€682.36K - Retained earnings
€6.70B - Other equity
€0.00 - Total equity
€6.12B - Total liabilities and shareholders' equity
€6.75B
Company information
- Market capitalization
€10.94B - Employees
1.3K - Enterprise Value
€10.77B
Company ratios
- Gross margin
-
89.0% Much better than peer group: -13,434.7% - EBITDA margin
-
51.6% Much better than peer group: -48,904.6% - EBIT margin
-
47.0% Much better than peer group: -50,446.8% - EBT margin
-
52.5% Much better than peer group: -50,623.9% - Net margin
-
40.4% Much better than peer group: -50,638.9% - ROE
-
17.3% Much better than peer group: -19.7% - ROA
-
15.7% Much better than peer group: -47.7% - Asset turnover
-
38.9% Much better than peer group: 18.1% - FCF margin
-
34.8% Much better than peer group: -49,517.4% - FCF yield
8.4% - Efficiency ratio
48.4% - Net sales per employee
-
€2.01M - Net income per employee
-
€811.84K